An interventional study of Blood punction in Prognosis Biomarker of AD, Mild Cognitive Impairment and Brain Insuline Resistance, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Basic research data from the literature on the links between cerebral insulin resistance and Alzheimer's disease (AD) suggest that this pathophysiological mechanism is involved at a very early stage in the development of the disease.
The insulin receptor (IR) is a tyrosine kinase receptor whose activation by insulin binding leads to autophosphorylation of its IRβ subunits and then of the insulin receptor substrate proteins (IRS-1). The ratio of IRS residues phosphorylated on serine 312 (P(Ser312)-IRS-1) to total phosphorylated IRS or IRS phosphorylated on its tyrosines has been proposed by some authors as an index of insulin resistance in the brain. IRS-1 proteins can be measured in exosomes, and in particular in neuronal exosomes isolated from plasma. It is therefore conceivable to measure this index in these biological samples specifically derived from neurons and available from a simple blood test, in order to determine whether it could be of prognostic interest in patients with mild cognitive impairment (MCI), in particular by making it possible to identify at an early stage patients who are going to convert to AD.
Basic research data from the literature on the links between cerebral insulin resistance and AD suggest that this pathophysiological mechanism is involved at a very early stage in the development of the disease. The multiple effects of insulin on cerebral bioenergetic regulation, synaptic viability, dendritic spine formation and neurotransmitter turnover, as well as on the clearance and degradation of Aβ peptide, All these factors suggest that dysregulation of insulin signalling pathways in the brain may contribute early on to neurodegeneration in AD, and represent both a therapeutic lever and a source of biomarkers relevant to diagnosis and prognosis (1). Several clinical trials are currently underway to validate the value of insulin administration or the use of drugs that affect insulin receptor sensitivity in the treatment of AD patients (2).
Given these arguments in favour of the role of cerebral insulin resistance in the early stages of AD, being able to measure such an index in plasma could prove invaluable in the management of patients. However, it is still difficult to distinguish between peripheral and central origin of the molecules measured, which explains the frequent use of lumbar puncture to diagnose neurological diseases. An alternative strategy could be based on the specific isolation of neuronal exosomes present in the blood. Exosomes are vesicles derived from late endosomes and containing nucleic acids, proteins and lipids. Specific protein markers, such as L1CAM for neurons, enable them to be isolated by immunoaffinity, according to their cellular origin. It is then possible to measure plasma biomarkers whose neuronal origin is certain (4).
IRS-1 proteins can be measured in exosomes, and in particular in neuronal exosomes isolated from plasma, but studies on the use of this index in AD are rare. One team of researchers has taken a particular interest in this question, showing that the insulin resistance index is significantly higher in AD patients than in control subjects or those with another neurodegenerative disease (3). A more recent study also showed that, in Alzheimer's subjects, brain volume was positively correlated with the level of IRS-1 phosphorylated on its tyrosine residues, whereas it was negatively correlated with the level of IRS-1 phosphorylated on serine 312 (5). This index in exosomes has also been proposed to distinguish good from poor responders to insulin treatment (6) or to illustrate the links between amyloid and Tau pathologies in AD (7). To date, no study has proposed using this index in plasma neuronal exosomes as a marker of conversion to AD in patients with mild cognitive impairment.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
This study's planned enrollment of 122 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Men or women aged 18 to 75 followed for mild cognitive disorders at the Nancy CHRU CMRR for 1 to 2 years
Biological: Blood punction
At each annual visit (+/- 3 months), 4X10 mL blood will be taken (1 dry tube, 1 heparinised tube, 2 EDTA tubes)
prognostic performance of insulin resistance indexes
Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value of Pser312-IRS1/Ptyr-IRS1 and Pser312-IRS1/IRS1 ratios measured at t0 (inclusion visit) Threshold value for these ratios to predict conversion to AD to be defined (no thresholds for these ratios in the literature) Conversion to AD defined by the clinician according to usual practice
Time frame: 3 years
prognostic performance of insulin resistance indexes in diabetic and non-diabetic MCI patients
Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value of Pser312-IRS1/Ptyr-IRS1 and Pser312-IRS1/IRS1 ratios measured at t0 (inclusion visit) Threshold value for these ratios to predict conversion to AD to be defined (no thresholds for these ratios in the literature) Conversion to AD defined by the clinician according to usual practice
Time frame: 3 years
Link between cerebral insulin resistance index and conversion time
Time between date of first symptoms and date of conversion to AD in months Value of Pser312-IRS1/Ptyr-IRS1 and Pser312-IRS1/IRS1 ratios measured at t0 (inclusion visit) Conversion to AD defined by the clinician according to usual practice
Time frame: 3 years
Link between cerebral insulin resistance index and glycated haemoglobin level
Pser312-IRS1/Ptyr-IRS1 and Pser312-IRS1/IRS1 ratios measured at t0 (inclusion visit) HbA1c in % measured at t0 (inclusion visit)
Time frame: 3 years
Link between cerebral insulin resistance index and vascular resistance
Pser312-IRS1/Ptyr-IRS1 and Pser312-IRS1/IRS1 ratios measured at t0 (inclusion visit) Vascular resistance measured at t0 (inclusion visit)
Time frame: 3 years
No study locations are listed for this record.
Start is estimated for Mar 2025; primary completion for Sep 2027, 29 months later.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 29 months is close to that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →